Bacil Pharma Ltd (524516)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 14 அக். 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 29 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Bacil Pharma Ltd reported Q2 FY27 results on 14 Oct 2026: revenue ₹0.0 Cr, and net profit ₹-0.1 Cr.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.0 | — | — |
| செயல்பாட்டு லாபம் | ₹-0.1 | — | — |
| நிகர லாபம் | ₹-0.1 | — | — |
| EPS (₹) | 0.06 | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Bacil Pharma Limited announced that its wholly owned subsidiary, Bacil Research and Development Private Limited, has entered into an agreement with Efdee Pharma Private Limited on November 4, 2026. The scope includes R&D activities for pharmaceutical products such as pellets, granules, powders, tablets, and capsules. The total estimated project cost is ₹35 crore, which is significant relative to the company's net worth of ₹25 crore. Specific financing terms, milestones, and commercialization timelines were not detailed in the filing.
- Agreement executed on 04/11/2026 by wholly owned subsidiary Bacil Research and Development Private Limited
- Partnered with Efdee Pharma Private Limited for pharmaceutical R&D activities
- Estimated project cost is ₹35,00,00,000 (₹35 crore)
- Project scope covers pellets, granules, powders, tablets, and capsules
Bacil Pharma reported unaudited financial results for the quarter ended September 30, 2026, recording ₹0 in revenue from operations. Total revenue consisted entirely of other income at ₹9.18 lakh, compared to ₹105.74 lakh in Q2 FY26. Total expenses stood at ₹5.93 lakh, leading to a profit before tax of ₹3.38 lakh. Aided by other comprehensive income of ₹16.27 lakh, total comprehensive income for the period reached ₹15.29 lakh.
- Revenue from operations remained at ₹0.00 for the quarter ended September 30, 2026
- Other income stood at ₹9.18 lakh vs ₹105.74 lakh in the corresponding prior-year quarter
- Total expenses were ₹5.93 lakh, primarily driven by other expenses of ₹5.15 lakh
- Profit before tax stood at ₹3.38 lakh against ₹91.20 lakh in Q2 FY26
- Cash and cash equivalents declined to ₹30.31 lakh as of September 30, 2026
Bacil Pharma announced the resignation of its Whole-Time Company Secretary and Compliance Officer, Mr. Dikshant Singh Panwar, effective October 8, 2026. The resignation was accepted on the same day, citing personal and professional commitments. The company stated it is currently taking steps to appoint a successor to meet statutory requirements. Bacil Pharma has a micro-cap size of Rs 30 Cr and recorded zero revenue over recent quarters.
- Resignation of Whole-Time Company Secretary and Compliance Officer Dikshant Singh Panwar
- Effective date of resignation accepted as October 8, 2026
- Company is in the process of appointing a replacement as mandated by SEBI LODR
Bacil Pharma Limited has submitted its Annual Report for FY 2025-26 along with the notice for its 39th Annual General Meeting scheduled for September 23, 2026. The agenda includes the adoption of audited financial statements for FY26 and the redesignation of Ms. Chaitali Kalpataru Shah from Executive Director to Managing Director until July 28, 2029. Additionally, the company seeks shareholder approval for the appointment of independent directors and statutory auditors.
- 39th Annual General Meeting to be held virtually on September 23, 2026, at 03:00 P.M. IST
- Special resolution proposed for change in designation of Ms. Chaitali Kalpataru Shah to Managing Director up to July 28, 2029
- Non-current investments stood at ₹2423.97 lakh as of March 31, 2026
- Cash and cash equivalents reported at ₹56.85 lakh as of March 31, 2026 compared to ₹4.15 lakh in FY25
Bacil Pharma Limited has issued the notice for its 39th Annual General Meeting scheduled for September 23, 2026, via video conferencing. Key agenda items include the adoption of FY26 audited financial statements and the designation change of Chaitali Kalpataru Shah to Managing Director through July 28, 2029. The company also seeks member approval for appointing new independent and non-executive directors. Financially, the micro-cap company (market cap of ~₹16 Cr) generated ₹0 Cr in operating revenue with a net profit of ₹1.34 Cr in FY26.
- 39th Annual General Meeting to be held on September 23, 2026, at 03:00 PM IST via video conferencing.
- Proposed elevation of Chaitali Kalpataru Shah (DIN: 11167778) to Managing Director for a term ending July 28, 2029.
- Resolutions include appointment regularisation of Independent Directors Vivek Mukesh Yadav, Omprakash Pyarelal Sonar, and Mahesh Singh.
- Company reported FY26 net profit of ₹1.34 Cr on ₹0 Cr topline with promoter holding currently at 0.0%.
Bacil Pharma Ltd has notified stock exchanges of its book closure period from September 17, 2026, to September 23, 2026 (both days inclusive). The closure is for the purpose of conducting its 39th Annual General Meeting scheduled on September 23, 2026. The company confirmed that no dividend has been declared for the financial year 2025-2026. Bacil Pharma reported Rs 0 Cr revenue in FY26 and has a market cap of approximately Rs 16 Cr.
- Book closure scheduled from 17/09/2026 to 23/09/2026 (both days inclusive)
- 39th Annual General Meeting (AGM) to be held on September 23, 2026
- No dividend declared for the financial year 2025-2026
Bacil Pharma Limited has approved the notice convening its 39th Annual General Meeting (AGM) on September 23, 2026. A key resolution includes increasing the company's Authorised Share Capital from ₹20.00 crore to ₹70.00 crore (7,00,00,000 equity shares of ₹10 each), providing substantial headroom for future equity issuances. The Board has also sought shareholder approval for redesignating Chaitali Kalpataru Shah as Managing Director until July 28, 2029, and appointing M/s Sarang Shivajirao Chavan & Associates as Statutory Auditors for four financial years.
- Proposed increase in Authorised Share Capital from ₹20.00 crore to ₹70.00 crore (7 crore equity shares of ₹10 each).
- 39th Annual General Meeting scheduled for Wednesday, September 23, 2026 at 3:00 PM IST via VC/OAVM.
- Proposed change in designation of Chaitali Kalpataru Shah to Managing Director with tenure up to July 28, 2029.
- Proposed appointment of M/s Sarang Shivajirao Chavan & Associates, Chartered Accountants, as Statutory Auditors until conclusion of 43rd AGM.
Bacil Pharma Ltd has scheduled a meeting of its Board of Directors for August 29, 2026. The board will consider and approve the notice for the 39th Annual General Meeting (AGM) and the Directors' Report for FY 2025-2026. The board will also finalize the date, time, and venue for the upcoming AGM. This is a routine administrative filing in line with annual compliance requirements.
- Board meeting scheduled for August 29, 2026
- Agenda includes approval of the Directors' Report for FY 2025-2026
- Board to finalize the notice, date, time, and venue for the 39th AGM
Bacil Pharma Limited has announced the appointment of two additional directors to its Board, effective August 25, 2026. Mr. Mahesh Singh has been appointed as an Additional Non-Executive Independent Director, bringing over seven years of sales and marketplace experience. Mr. Anil Shiv Charan Singh has been appointed as an Additional Non-Executive Director to support business management and commercial operations. Both appointments are subject to shareholder approval.
- Appointment of Mr. Mahesh Singh (DIN: 11814569) as Additional Independent Director effective August 25, 2026
- Appointment of Mr. Anil Shiv Charan Singh (DIN: 09338444) as Additional Non-Executive Director effective August 25, 2026
- Board meeting held on August 25, 2026, commencing at 3:30 P.M. and concluding at 4:30 P.M.
- Appointments are subject to member approval in accordance with applicable provisions
Bacil Pharma Limited has informed the exchange that a meeting of its Board of Directors is scheduled for Tuesday, August 25, 2026. The primary agenda item is to discuss the appointment of directors to the board. Bacil Pharma currently operates with a market capitalization of Rs 19 Cr, zero TTM revenue, and 0.0% promoter holding.
- Board meeting scheduled to be held on August 25, 2026.
- Key agenda includes discussion on the appointment of Directors.
- Notice issued in compliance with Regulation 29(1) of SEBI LODR Regulations on August 17, 2026.
Bacil Pharma reported zero operational revenue for the quarter ended June 30, 2026, continuing its trend of no core business activity. The company posted a net loss of ₹1.61 lakhs, a sharp decline from a profit of ₹66.90 lakhs in the same quarter last year, as other income plummeted 91% to ₹8.91 lakhs. While Total Comprehensive Income was positive at ₹30.12 lakhs, this was entirely due to a ₹31.73 lakh gain from the fair valuation of financial assets rather than business operations.
- Revenue from operations remained at ₹0.00 for the quarter ended June 30, 2026.
- Net loss of ₹1.61 lakhs recorded against a profit of ₹66.90 lakhs in the year-ago period.
- Other income fell 91.1% YoY to ₹8.91 lakhs from ₹100.30 lakhs in June 2025.
- Total Comprehensive Income of ₹30.12 lakhs was supported by a ₹31.73 lakh gain on financial asset valuation.
- Promoter holding remains at 0.0%, indicating a lack of skin in the game from original founders.
Bacil Pharma Ltd has scheduled a board meeting for August 12, 2026, to review and approve its unaudited financial results for the quarter ended June 30, 2026. The company is currently a micro-cap entity with a market capitalization of Rs 27 Cr and has reported zero operational revenue over the trailing twelve months. Investors should note the unusual 0% promoter holding and the significant 67.1% decline in stock price over the last three months.
- Board meeting scheduled for August 12, 2026, to approve quarterly results
- Company reports Rs 0 Cr revenue for the trailing twelve months (TTM)
- Promoter holding has reached 0.0% as of the March 2026 quarter
- Stock has experienced a 12-month price return of -50.1%
Bacil Pharma has incorporated a new wholly-owned subsidiary, Bacil Research & Development Private Limited, on July 28, 2026. This structural change occurs while the parent company reports zero TTM revenue and a 0.0% promoter holding. While the new entity suggests a focus on R&D, the filing does not disclose the initial capital infusion or specific business objectives. Given the company's current market cap of Rs 38 Cr and lack of operational revenue, the impact of this new entity remains speculative.
- Incorporation of Bacil Research & Development Private Limited as a 100% subsidiary on July 28, 2026
- Parent company reports Rs 0 Cr TTM revenue as of the latest financial context
- Promoter holding in the parent company has dropped to 0.0% as of March 2026
- Company market capitalization stands at a micro-cap level of Rs 38 Cr
Bacil Pharma's board has approved a significant fundraise of up to ₹50 crore through a Rights Issue of equity shares. To accommodate this, the company is increasing its authorized share capital by ₹45 crore, bringing the total to ₹65 crore. Concurrently, two independent directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, resigned effective July 9, 2026, citing time constraints. The exchange brief indicates these resignations follow a query raised by the BSE, adding a layer of regulatory scrutiny to the capital-raising plans.
- Approved fundraise of up to ₹50,00,00,000 (₹50 crore) via Rights Issue to existing shareholders.
- Authorized share capital increased by ₹45,00,00,000 to a new total of ₹65,00,00,000.
- Resignation of 2 Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, effective July 9, 2026.
- Appointment of Acuite Ratings & Research Limited as the Monitoring Agency for the issue.
- Formation of a Rights Issue Committee chaired by Executive Director & CFO Chaitali Kalpataru Shah.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
